Clinical characteristics of roxatidine acetate: a review.

Pharmacodynamic studies revealed that 150 mg of roxatidine acetate were optimal in suppressing gastric acid secretion, and that a single bedtime dose of 150 mg was more effective than a dose of 75 mg twice daily in terms of inhibiting nocturnal acid secretion. When administered orally as a capsule containing a granule formulation, the drug displayed modified-release properties, which led to a sustained suppression of gastric acid secretion. Clinical trials revealed that roxatidine acetate, 75 mg twice daily and 150 mg at night, was highly effective in healing duodenal and gastric ulcers and in reducing ulcer pain, over 4, 6, and 8 weeks of therapy. A steady reduction in diameter was observed in those ulcers not completely healed during therapy. The single bedtime dose regimen, while producing the same degree of healing as the divided daily dose during controlled clinical trials, may be of greater value in therapeutic use owing to improved patient compliance. In all efficacy criteria (cure, reduction in ulcer size, and pain relief) there was no significant difference between roxatidine acetate in a total daily dose of 150 mg, ranitidine in a total daily dose of 300 mg, and cimetidine in a total daily dose of 800 mg. Prevention of gastric and duodenal ulcer relapse was achieved by roxatidine acetate, 75 mg at night for 6 months, in about 70% of patients, as determined in open, pilot studies--a rate comparable to those reported for cimetidine and ranitidine. Roxatidine acetate shares with ranitidine an improved safety profile when compared with cimetidine. Human pharmacology studies and short-term and long-term clinical trials have all shown that roxatidine acetate is an exceptionally well tolerated compound, without the antiandrogenic activity and interference with hepatic drug metabolism which have characterized cimetidine treatment. A reason for the improved safety profile of roxatidine acetate may be its greater potency than cimetidine (six times less potent) and ranitidine (half as potent), so that lower doses of roxatidine acetate, representing a lower chemical load, are therapeutically effective. The novel structure of roxatidine acetate probably also underlies the improved safety of the compound.

Biochemistry and genetics of esterase-20 (ES-20), a second trimeric carboxylesterase of the house mouse (Mus musculus). I. Purification and characterization of ES-20C1 from male kidney.

ES-20 was isolated from male mouse kidney and purified 350-fold by ion-exchange chromatography, isoelectric focusing, and gel filtration. The resultant product was apparently homogeneous by the criteria of polyacrylamide gel electrophoresis and immunodiffusion and represented a major fraction of male mouse kidney esterase. Sodium dodecyl sulfate gel electrophoresis revealed the presence of a single subunit band, molecular weight 59,500; the molecular weight of the native protein was found to be 179,000. Titration of the active site yielded an equivalent weight of about 175,000. The enzyme was further characterized by its kinetic parameters for the hydrolysis of a series of 4-nitrophenyl esters and was classified as a carboxylesterase (EC 3.1.1.1). ES-20C1 bound to concanavalin A, indicating that it was a high-mannose-type glycoprotein; the role of terminal beta-N-acetylglucosamine residues in the carbohydrate side chains for stabilization of the quaternary structure of the trimer was revealed. Extensive biochemical and immunological similarities to ES-9C supported an earlier suggestion that the Es-9c gene product is a component of the ES-20C1 trimer.

Biochemistry and genetics of esterase-20 (ES-20), a second trimeric carboxylesterase of the house mouse (Mus musculus). II. A unique recombination reveals ES-20 as a hybrid enzyme.

A unique recombination is described between (Es-1, Es-6) and (Es-9, Es-22) within gene cluster 1 of the esterase gene region on chromosome 8 of the house mouse. This recombination established the gene order Es-1--Es-6--(Es-9, Es-22)--Got-2. A further 73 recombinations, from a total of 911 backcrosses, had taken place between cluster 1 and cluster 2. A distance between the clusters of 8.01 +/- 0.90% was calculated; the genes within the clusters appeared more tightly linked than previously assumed. ES-20 behaved anomalously following the recombination within cluster 1: homozygous descendants of the recombinant expressed a new form of ES-20. In vitro incubation of purified ES-6A3 and ES-9A generated ES-20A, revealing this esterase to be a hybrid of different cluster 1 gene products, Es-9 and possibly Es-6. This result satisfactorily accounted for the genetic finding, as well as a range of biochemical properties of ES-20.

Identification and development of a genetically closely-linked carboxylesterase family of the mouse liver.

Six carboxylesterase isozymes (viz. ES-1, ES-6, ES-9, ES-20, ES-22 and ES-24), governed by esterase gene cluster 1 on chromosome 8 of the house mouse, were identified electrophoretically in liver supernatants using their biochemical, genetic and developmental characteristics. ES-1 and ES-20 were expressed as liver-specific forms. The peri- and postnatal development of the six isozymes indicated that they were individually regulated at the genetic level, although the isozymes were regulated as a group when compared to genetically unrelated esterases. The concept of evolutionary divergence following repeated gene duplication of an ancestral esterase structural gene was extended to cover divergence of the temporal (regulatory) genes associated with the multigene family. Allelic variation of the temporal genes was more limited than that of the corresponding structural genes.

Organ specific expression of esterase-6 in the house mouse, Mus musculus.

Esterase-6 in fresh homogenates of heart muscle and testis of the house mouse shows a two band (C allele) or three band (A allele) pattern in disc electrophoresis. These primary bands generated in series of secondary bands upon lowering the pH of the homogenates, and the secondary pattern, possibly resulting from partial proteolysis, was seen in varying degrees in fresh homogenates from a range of organs. Interrelationships between the primary and secondary bands were demonstrated by isoelectric focusing. The esterase-6 content of twenty different organ homogenates was estimated from electrophoretic gels, and a high level of this enzyme was observed in those organs most actively involved in fat metabolism. The possible participation of esterase-6 in fatty acid utilization is discussed. Similarities between esterase-6 of the house mouse and esterase-4 of the rat were demonstrated, further strengthening the view that these enzymes are homologous.